Research the development of endoxaban as well as the target and Essay

Research the development of endoxaban as well as the target and mechanism of action. Illustrate aspects of the discovery and development process that are relevant to endoxaban - Essay Example , however jus most recently in the January of 2015.1 In the USA, the drug has been approved both for the prevention of the systematic formation of blood clot in the non–central-nervous-system, as well as for the prevention of stroke1. The drug is currently approved for medical use in the treatment of the thrombosis of deep veins, as well as in the treatment of pulmonary embolism, after a period of 5 to 10 days therapy involving the application of a parenteral-based coagulant.3 The development of the Endoxaban oral drug started several years ago, but the first official request for investigation and approval by the Daiichi Sankyo company was made to the Ministry of Health in Japan in 6 April 2010.2 The investigation of the drug commenced and the approval of its commercial production and sale was approved in Japan by the Ministry of Health on 22 April 2011, making the drug a fully approved medication for the prevention of venous thromboembolisms (VTE).4 At the international level, the drug has undergone successful investigations, with the first clinical investigation being initiated towards the end of 2009, where a clinical study was undertaken usinig 21,000 patients in the USA, Europe and Japan.3 The second clinical trial was subsequently undertaken in Japan, followed by the third clinical investigations, all of which have demonstrated the efficacy and safety profile of oral Endoxaban when comparable to that of warfarin, which is the most common used antico agulant in the USA.4 The first clinical investigations of the drug, since the drug was first subjected to clinical investigations in 2009, has indicated that the drug has the acceptable profile of both safety and efficacy of use for medication.5 The second and the third phases of the clinical investigations have affirmed the safety and efficacy profiles of the oral Endoxaban, resulting in its approval for the medical use in the prevention of both venous clotting and stroke. Despite the fact that the Endoxaban